Skip to main content
Premium Trial:

Request an Annual Quote

Court Permanently Bars Stratagene from Selling FullVelocity Products; Company Vows to Appeal

NEW YORK, Sept. 30 (GenomeWeb News) - A US district court has permanently barred Stratagene from selling its FullVelocity QPCR and QRT-PCR products, which the court said  infringe two patents held by Third Wave Technologies, Third Wave said yesterday.

 

The injunction, issued by the US District Court for the Western District of Wisconsin, prohibits Stratagene from manufacturing, selling, and offering these or any other products that violate Third Wave's US patents Nos. 6,090,543 and 6,348,314. Stratagene must also notify its customers and collaborators about the infringement.

 

Earlier this month, a jury found that Stratagene willfully infringed Third Wave's patents and awarded Third Wave $5.29 million in damages. Third Wave, which  filed the suit last September, said it is seeking additional damages and expects a decision by the court by the end of the year.

 

Stratagene said today in a response that it intends to file an appeal in the Court of Appeals for the Federal Circuit in Washington, DC, "as soon as practicable." The company will seek to have the injunction lifted and the damages reduced or eliminated.

 

On May 6, Stratagene  countersued Third Wave in the US District Court for the District of Delaware, which is still pending, claiming that Third Wave infringes its Full Velocity technology. Stratagene seeks monetary damages and a permanent injunction to prevent Third Wave from selling its Invader Plus products.

 

Stratagene reiterated today that its infringing Full Velocity products have contributed less than $400,000 in revenues since they were made available last year, and that other embodiments of the FullVelocity technology do not infringe Third Wave's patents.

The Scan

Support for Moderna Booster

An FDA advisory committee supports authorizing a booster for Moderna's SARS-CoV-2 vaccine, CNN reports.

Testing at UK Lab Suspended

SARS-CoV-2 testing at a UK lab has been suspended following a number of false negative results.

J&J CSO to Step Down

The Wall Street Journal reports that Paul Stoffels will be stepping down as chief scientific officer at Johnson & Johnson by the end of the year.

Science Papers Present Proteo-Genomic Map of Human Health, Brain Tumor Target, Tool to Infer CNVs

In Science this week: gene-protein-disease map, epigenomic and transcriptomic approach highlights potential therapeutic target for gliomas, and more